Omeros presents new gpr174 immuno-oncology data at the american association for cancer research conference in boston
Omeros corporation announced new findings on gpr174, its novel cancer immunotherapy target, demonstrating that gpr174-deficiency enhances anti-tumor immune responses in animals. the studies were conducted in mouse models of melanoma and of colon carcinoma, each of which was modified to partially deplete regulatory t cells, a subset of immunosuppressive t cells. partial depletion of regulatory t cells in mice creates a t-cell composition more similar to that in humans. gpr174 deficiency in these mice resulted in significantly reduced tumor growth and improved survival of the animals (p=0.006 in melanoma; p=0.03 in colon cancer) versus normal mice. these findings are being presented by marc gavin, ph.d., omeros’ director of immunology, at the american association for cancer research conference on tumor immunology and immunotherapy in boston, massachusetts. the presentation also features discoveries regarding phosphatidylserine (ps), a product of cell stress and death that is abundant in the tumor microenvironment. ps has been shown by omeros to suppress t-cell activity through gpr174. the function of ps is similar to that of adenosine, which is also abundant in the tumor microenvironment and suppresses t cells through adenosine receptors. it was demonstrated that the combination of adenosine pathway inhibition together with omeros’ novel gpr174 inhibitors results in maximal potentiation of t-cell responses, which should translate to a more effective cancer immunotherapy approach.
OMER Ratings Summary
OMER Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission